{"entity":{"id":"idea-pretargeted-alpha-therapy","kind":"idea","name":"Pretargeted alpha radioimmunotherapy","aka":[],"tldr":"Instead of injecting a radioactive antibody that circulates in the blood for days, doctors first give a plain antibody that finds the tumour, wait for it to clear, then inject a small, fast-moving radioactive alpha payload that only attaches where the antibody is already waiting. This two-step trick could let radioactive antibodies treat solid tumours without poisoning the bone marrow.","summary":"Directly labelled antibodies carrying alpha emitters are attractive because alpha particles are extremely damaging over a very short range, but full-length antibodies circulate for days, so a directly labelled alpha antibody keeps irradiating blood and marrow long after most of it has left the tumour. Pretargeting separates the two steps: a bispecific antibody (one arm binds the tumour antigen, the other binds a small hapten) is given first and allowed to clear from circulation over hours to days, then a small radiolabelled hapten is injected and rapidly binds the antibody already sitting on the tumour, or clears from the body within hours if unbound.\n\nThe approach has a long clinical history with beta and gamma emitters going back over thirty years, including phase I/II trials of iodine-131 and lutetium-177 pretargeting in medullary thyroid cancer, small-cell lung cancer and CEA-positive colorectal cancer, but it has never reached market approval; a 2017 review notes that pretargeted lutetium-177/CEA trials in colorectal cancer were disappointing because tumour retention was too fast relative to lutetium-177's multi-day half-life. That mismatch is exactly why alpha emitters, most of which have half-lives of minutes to hours (bismuth-213, astatine-211), are now seen as a better fit for pretargeting's fast hapten kinetics. Preclinical proof of concept for alpha-pretargeting exists: a 2025 study from Memorial Sloan Kettering used a three-step regimen (anti-HER2/anti-DOTA bispecific antibody, a clearing agent, then actinium-225-labelled DOTA) to achieve complete responses in 20/20 HER2-positive breast cancer xenografts with tumour-to-kidney dose ratios of roughly 60:1 and no chronic nephrotoxicity at curative doses.\n\nNo alpha-emitter pretargeting regimen has yet been tested in patients; all current human experience with actinium-225 or bismuth-213 antibody therapy uses direct labelling (for example anti-CD33 225Ac antibodies in acute myeloid leukaemia).","asOf":"2026-09-22","links":[{"label":"225Ac alpha-pretargeted radioimmunotherapy of HER2-expressing breast cancer (J Nucl Med, 2025)","url":"https://jnm.snmjournals.org/content/early/2025/06/05/jnumed.125.269601"},{"label":"Pretargeting: A Path Forward for Radioimmunotherapy (PMC review)","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12079710/"},{"label":"Pretargeting for imaging and therapy in oncological nuclear medicine (PMC, 2017)","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5824696/"}],"tags":["alpha therapy","antibody","pretargeting"],"related":["targeted-alpha-therapy","radioimmunotherapy","her2","ceacam5","lu-177","ac-225","i-131","bi-213","at-211"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"A three-step pretargeting regimen (bispecific antibody, clearing agent, then an alpha-emitting hapten) will achieve a substantially higher tumour-to-normal-tissue radiation dose ratio than directly labelled alpha-emitting antibodies, enabling curative-intent alpha radioimmunotherapy of solid tumours without dose-limiting marrow or kidney toxicity.","rationale":"Mechanistically, pretargeting decouples the antibody's slow blood clearance from the radioactive payload's fast clearance, which matters most for alpha emitters whose half-lives (minutes to hours) are far shorter than an antibody's circulation time. Preclinical 225Ac-pretargeted radioimmunotherapy against HER2-positive breast cancer achieved 100% complete response and roughly 60:1 tumour:kidney dose ratios in two xenograft models without chronic nephrotoxicity at curative doses (Cheal, Santich et al., J Nucl Med 2025). Decades of clinical pretargeting experience exist with beta and gamma emitters (iodine-131, lutetium-177), establishing the two-step logistics and bispecific-antibody dosing are feasible in patients, but those beta-emitter trials had disappointing tumour retention. No alpha-emitter pretargeting regimen has been tested clinically.","test":"A first-in-human phase 1 dose-escalation trial of a pretargeted alpha regimen (bispecific antibody plus clearing agent, then an actinium-225- or bismuth-213-labelled hapten) in patients with a refractory HER2-positive or CEA-positive solid tumour, roughly 20-30 patients, with safety/maximum tolerated dose as the primary endpoint and surrogate imaging-based tumour dosimetry as a key secondary endpoint.","maturity":"preclinical-evidence","actor":"research","cost":"large","horizonYears":10},"route":"/ideas/idea-pretargeted-alpha-therapy/","neighbours":{"technology":[{"id":"radioimmunotherapy","kind":"technology","name":"Radio-antibody & radio-ADC","route":"/technologies/radioimmunotherapy/"},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/"}],"target":[{"id":"ceacam5","kind":"target","name":"CEACAM5","route":"/targets/ceacam5/"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"isotope":[{"id":"ac-225","kind":"isotope","name":"Actinium-225","route":"/isotopes/ac-225/"},{"id":"at-211","kind":"isotope","name":"Astatine-211","route":"/isotopes/at-211/"},{"id":"bi-213","kind":"isotope","name":"Bismuth-213","route":"/isotopes/bi-213/"},{"id":"i-131","kind":"isotope","name":"Iodine-131","route":"/isotopes/i-131/"},{"id":"lu-177","kind":"isotope","name":"Lutetium-177","route":"/isotopes/lu-177/"}]}}